Komori
Other Disclosures6090Human Metabolome Technologies,Inc.Information and Communications, Services and Others

Sales launched for a “Short-/Medium-Chain Fatty Acid Analysis Option” specializing in short- and medium-chain fatty acids attracting attention in healthcare

Sales have begun for the “Short-/Medium-Chain Fatty Acid Analysis Option,” which can measure short- and medium-chain fatty acids together with high sensitivity. The option can be added to the existing metabolome analysis service and is also compatible with blood samples.

Worth reading
48Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Announced details

短/中鎖脂肪酸分析オプション
Applicable field (uses covered by this announcement)

疾患研究、ヘルスケア、スポーツ医学、栄養学、脳腸相関の機序解明、研究開発

Launch date2025年11月7日(販売開始、実績)
What the company reported numerically
Quantitative Effects

高感度で精度の高い定量値を取得可能。存在量の少ない血液を用いた測定も可能

Impact on Business Performance

The impact on our financial results is minor.

The company does not address Contract Value / Offering price.

Announced details
ItemDetails
Names of Products / Services Covered短/中鎖脂肪酸分析オプション
Launch date2025年11月7日(販売開始、実績)
Applicable area疾患研究、ヘルスケア、スポーツ医学、栄養学、脳腸相関の機序解明、研究開発
Quantitative Effects高感度で精度の高い定量値を取得可能。存在量の少ない血液を用いた測定も可能
Impact on Business PerformanceThe impact on our financial results is minor.
Items this document does not state (13)
CounterpartyCounterparty overviewRelationship with the CompanyContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleUsage historySource

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

短鎖・中鎖脂肪酸は揮発性や反応性が高く従来手法では正確な定量が難しかったため、これらに特化した高感度分析手法を開発し、従来サービスにさらなる価値を付与するため。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Sales launched for a “Short-/Medium-Chain Fatty Acid Analysis Option” specializing in short- and medium-chain fatty acids attracting attention in healthcare | Human Metabolome Technologies,Inc. (6090) timely disclosure | Komori